Official Title
Multicenter, Randomized, Double-blind Parallel Group Pilot Study to Evaluate the Effect of the Consumption of a Lactobacillus Strain on the Incidence of Covid-19 in the Elderly
Brief Summary

The objective of this trial is to evaluate the effect of the consumption of a probiotic strain on the incidence and severity of COVID-19 in elderly population living in a nursing home. In addition, it will be evaluated if the probiotic strain have some effect on the immune response generated by the Covid-19 vaccine inthis population.

Detailed Description

The working hypothesis is that the administration of a Lactobacillus strain improves the
immune response in the elderly population, improving the immune response to a possible
COVID-19 infection. The strain would act as an adjuvant that contributes to developing an
effective response against the virus, and therefore there are fewer infectious symptoms due
to this virus or, if it appears, it occurs in a milder way among the subjects who take the
probiotic strain. Also,the investigators hypothesizes that the administration of the
Lactobacillus may improve the immune response generated by the Covid-19 vaccine in this
elderly population.

Unknown status
SARS CoV-2 Infection
Elderly

Dietary Supplement: Placebo

Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits

Dietary Supplement: Lactobacillus

Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits

Eligibility Criteria

Inclusion Criteria:

1. Person over 60 years of age.

2. Intern in residence for the elderly.

3. Sign informed consent.

Exclusion Criteria:

1. Person who at some previous time has tested positive for detection of COVID-19 by PCR
or serology.

2. Person who at the time of starting the intervention presents symptoms compatible with
COVID-19.

3. Person with concomitant disease type HIV, transplant, active cancer or other type of
active immunosuppression.

Eligibility Gender
All
Eligibility Age
Minimum: 60 Years ~ Maximum: N/A
Countries
Spain
Locations

Residencia San Marcos
Santiago De Compostela, A Coruña, Spain

Residencia Santa Olalla
Santiago De Compostela, A Coruña, Spain

Residencia San Simon de Ons
Santiago De Compostela, A Coruña, Spain

Biosearch S.A.
NCT Number
Keywords
probiotics
COVID19
MeSH Terms
COVID-19